Emergent BioSolutions (LTS:0IGA) Moat Score: 5/10 (As of Jul. 12, 2026)


LTS:0IGA Emergent BioSolutions Inc LTS:0IGA
60 GF Score
Price $7.96
GF Value $4.65
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Emergent BioSolutions Moat Score?

Emergent BioSolutions LTS:0IGA -1.73% 60 Moat Score is 5 as of Jul. 12, 2026. GuruFocus rates LTS:0IGA with a GF Score™ of 60/100 and a GF Value™ of $4.65 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Emergent BioSolutions ranks better than 94.67% on this metric.

Emergent BioSolutions has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Emergent BioSolutions has Narrow Moat: Emergent BioSolutions Inc has a solid narrow moat due to its valuable patents and government contracts, which provide some pricing power and regulatory barriers. However, its market share is not dominant, and it faces competition from larger pharmaceutical companies, limiting its moat to narrow.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Emergent BioSolutions might have Narrow Moat - Solid narrow moat.

Emergent BioSolutions  (LTS:0IGA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Emergent BioSolutions Moat Score Related Terms

LTS:0IGA vs ELTP, NIKA, EOLS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emergent BioSolutions Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Moat Score distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Moat Score falls into.


LTS:0IGA
60GF Score
Emergent BioSolutions Inc LTS:0IGA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Emergent BioSolutions (LTS:0IGA) has a Moat Score of 5 as of Jul. 12, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Emergent BioSolutions ranks #55 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Emergent BioSolutions' Moat Score too high?
Emergent BioSolutions' current Moat Score is 5. Based on the distribution chart, Emergent BioSolutions ranks #55 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Emergent BioSolutions has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Moat Score compare to ELTP and NIKA?
According to the Drug Manufacturers industry distribution chart, Emergent BioSolutions ranks #55 out of 1031 companies for Moat Score. This places Emergent BioSolutions in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Emergent BioSolutions's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (LTS:0IGA) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.65, compared to a current price of $7.96 — trading 71.2% above its estimated fair value. The current Moat Score is 5. Emergent BioSolutions' overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Emergent BioSolutions (LTS:0IGA), the current Moat Score is 5 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Emergent BioSolutions (LTS:0IGA) Overvalued in 2026?

Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued. The current stock price of $7.96 is trading 71.2% above its estimated GF Value™ of $4.65. GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.

Key valuation signals for LTS:0IGA:

  • Moat Score: 5
  • GF Value™: $4.65 vs. price of $7.96 (71.2% above fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the LTS:0IGA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Emergent BioSolutions Business Description

Other Exchanges EBS:USAER4:Germany
Address 300 Professional Drive, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
60GF Score

Get the complete analysis for LTS:0IGA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.96
Price
$4.65
GF Value